Comparison between CDE and R-CDE
| . | CDE (95% CI) . | R-CDE (95% CI) . |
|---|---|---|
| No. of patients | 55 | 74 |
| Median age, y | 40 | 38 |
| Median CD4 count/μL | 227 | 161 |
| Histology, % | ||
| Burkitt or Burkitt-like | 22 | 28 |
| Diffuse large cell or variants | 78 | 72 |
| Age-adjusted IPI, % | ||
| Low or low intermediate | 42 | 43 |
| High or high intermediate | 58 | 57 |
| Complete remission rate, % | 45 (30–58) | 70 (59–81) |
| Disease-free survival at 2 y, % | 38 (25–51) | 59 (47–71) |
| Overall survival at 2 y, % | 45 (20–58) | 64 (52–76) |
| . | CDE (95% CI) . | R-CDE (95% CI) . |
|---|---|---|
| No. of patients | 55 | 74 |
| Median age, y | 40 | 38 |
| Median CD4 count/μL | 227 | 161 |
| Histology, % | ||
| Burkitt or Burkitt-like | 22 | 28 |
| Diffuse large cell or variants | 78 | 72 |
| Age-adjusted IPI, % | ||
| Low or low intermediate | 42 | 43 |
| High or high intermediate | 58 | 57 |
| Complete remission rate, % | 45 (30–58) | 70 (59–81) |
| Disease-free survival at 2 y, % | 38 (25–51) | 59 (47–71) |
| Overall survival at 2 y, % | 45 (20–58) | 64 (52–76) |
Data are from Spina et al.141
CDE indicates cyclophosphamide, doxorubicin, etoposide; and R, rituximab.